SecBot SecBot
SECBOTREPLAY Home › Report › MESO

MESO · Mesoblast announced it has enrolled the target of 300 patients in the…

MESOBLAST LTD · 6-K filed Jul 14, 2026 at 07:54 ET

At the news

BULLISHIMPACT 6/10

6-K filed Jul 14, 2026 at 07:54 ET

Mesoblast announced it has enrolled the target of 300 patients in the pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. Top-line results are expected in mid-CY2027. The trial has RMAT designation from the FDA, and the company is proceeding with commercial manufacturing in parallel. This milestone de-risks the program but does not provide efficacy data.

  • At least 300 patients treated in the placebo-controlled pivotal Phase 3 trial of rexlemestrocel-L for CLBP.
  • Top-line results expected in mid-CY2027 after the last patient completes 12-month follow-up.
  • Rexlemestrocel-L has FDA RMAT designation, providing eligibility for priority review upon BLA filing.
  • Management estimates potential peak year revenue of >$10 billion with single-digit market penetration (forward-looking statement).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access